Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Fluidigm to Acquire DVS Sciences

Published: Wednesday, January 29, 2014
Last Updated: Wednesday, January 29, 2014
Bookmark and Share
The acquisition consideration of approximately $207.5 million consists of a combination of Fluidigm common stock and cash.

Continuing its strategy of delivering disruptive single-cell analysis capabilities to life science researchers around the world, Fluidigm Corporation has entered into a definitive agreement to acquire DVS Sciences, Inc. to create a single-cell technology powerhouse. Combined with DVS, Fluidigm will be able to offer a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.

DVS is best known for its multi-parameter single-cell protein analysis systems. DVS’s principal product is the CyTOF®2 Mass Cytometer, which analyzes antibody/metal complexes using atomic mass spectrometry. The technology enables high-parameter single-cell protein analysis for applications in biological research.

Fluidigm expects to fund the cash portion of the acquisition consideration primarily using proceeds from a proposed convertible notes offering. Subject to customary closing conditions, the transaction is currently expected to close in February 2014, at which point DVS would become a wholly-owned subsidiary of Fluidigm.

“We have long been interested in companies whose technologies are directly in-line with our strategy, have strong top-line growth, and whose management teams fit Fluidigm culturally and would be committed to the success of the combined enterprise. We waited for the perfect fit and believe we have found such a gem with DVS Sciences,” said Gajus Worthington, Fluidigm President and Chief Executive Officer. “DVS’s mass cytometry technology combines the advantages of high-throughput flow cytometry with the accuracy and resolution of mass spectrometry, enabling high-parameter single-cell protein analysis. We believe the acquisition of DVS will increase Fluidigm’s single-cell revenue immediately, as well as increase our addressable market to include the approximately $300 million high-end research flow cytometry segment. It also expands our analytical breadth to include single-cell protein analysis.”

"The merger of DVS with Fluidigm will provide exciting new product synergies around single-cell analysis for our customers as well as increased support networks and a wider reach into new markets,” said Joe Victor, President and Chief Executive Officer of DVS. "DVS is excited to be able to have the opportunity to jointly develop with Fluidigm new technologies, products and applications for our target life sciences markets.”

“At DVS, our goal has been to accelerate life sciences research and transform drug discovery via high-parameter bio-analysis. Early on we recognized that studying biology at the single-cell level provides new and important scientific insight. Researchers increasingly need high dimensional, single-cell analysis. The combination of DVS’s technology for protein analysis and Fluidigm’s technology for nucleic acid analysis provides researchers with solutions that could transform single-cell analysis for life sciences research, drug development, and potentially diagnostics,” said Dr. Scott Tanner, DVS’s Chief Technology Officer and Co-Founder. “We are delighted to join Fluidigm to champion the power of single-cell analysis and help pave the way for future breakthrough discoveries in biology.”

Several members of DVS’s management, operations and research and development teams – including Co-Founders Tanner, Dmitry Bandura, and Vladimir Baranov will join Fluidigm, subject to closing of the merger, to drive the integration of the organizations and support the continued growth of the combined business into the future.

Piper Jaffray & Co. is acting as exclusive financial advisor to Fluidigm and Wilson Sonsini Goodrich & Rosati P.C. is serving as Fluidigm's legal counsel. Jefferies LLC is acting as exclusive financial advisor to DVS and Latham & Watkins LLP is serving as DVS's legal counsel.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluidigm, OpGen Collaborate
Fluidigm and OpGen have announced an agreement to collaborate on instruments and kits to test for multi-drug resistance genes in bacteria, fungi, and viruses.
Tuesday, July 14, 2015
Singapore Single-Cell Research Centre Opens Door for Asian Biological Discoveries
Centre dedicated to diagnosis and treatment derived from single-cell exploration.
Monday, April 29, 2013
Fluidigm Announces $60 Million Public Offering of Common Stock
Company has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million.
Wednesday, August 22, 2012
Fluidigm Announces Unrestricted Sales into Prenatal Health
Fluidigm collaboration ends.
Tuesday, June 19, 2012
New Research Center to Focus on Mammalian Single Cell Genomics
New Center will feature a complete suite of Fluidigm single-cell tools, protocols and technologies.
Friday, June 15, 2012
Fluidigm China Opens Its Doors
Company expects to rapidly build strong presence in country and improve services to Chinese customer base.
Monday, April 23, 2012
Fluidigm and AH Diagnostics Sign Distribution Deal for Scandinavia
AH diagnostics will offer Fluidigm's complete portfolio, including the complete line up of Dynamic Array(TM), Digital Array(TM) and Access Array IFCs for real-time PCR, digital PCR, single-cell gene expression, sample preparation for next-generation sequencing, and SNP genotyping.
Tuesday, January 31, 2012
Fluidigm and Life Technologies Cross-License a Broad Set of Intellectual Properties
Fluidigm Corporation announces that it has entered into a set of cross-licensing and sub-licensing agreements on a range of intellectual properties with Life Technologies.
Tuesday, July 12, 2011
Fluidigm Reports Financial Results for First Quarter 2011
Total revenue for the first quarter of 2011 was $8.7 million, an increase of 30% from $6.7 million in the first quarter of 2010.
Wednesday, May 11, 2011
Fluidigm Announce Israeli Distribution Deal
Fluidigm has appointed Eisenberg Brothers as distributor in Israel and Eisenberg Brothers offers Fluidigm's complete portfolio of BioMark™, EP1™, and Access Array™ systems.
Tuesday, March 01, 2011
Research Newsletter for Biochip User Community
Fluidigm announces availability of the Fall 2010 edition of its community newsletter.
Tuesday, October 19, 2010
Modelling the Genetic Circuitry of Cell-to-Cell Communication
Stanford researchers used Fluidigm support instrumentation for analysis and modeling on how biological systems operate at the cellular level.
Thursday, July 15, 2010
Pathway-Focused Gene Expression Panels Validated for Real-time PCR
Fluidigm and SABiosciences team up to create gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System.
Thursday, April 08, 2010
Fluidigm and Qiagen's SABiosciences Team up to Provide Over 100 PCR Gene Expression Panels for Biomark Systems
Fluidigm Corporation and SABiosciences (a QIAGEN Company) today announced that they have teamed up to create over 100 pathway-focused gene expression panels validated for real-time PCR analysis on the Fluidigm BioMark™ System for Genetic Analysis.
Thursday, March 25, 2010
Fluidigm and Nano Gen Teknolojileri Team Up in Turkish Distribution Deal
Agreement brings integrated fluidic circuit technology to Turkish scientists specializing in digital and real-time.
Thursday, October 29, 2009
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
Detecting When Hormone Treatment for Breast Cancer Stops Working
Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment.
Packaging and Unpacking of the Genome
New research improves understanding of the importance of histone replacement.
New Way to Find DNA Damage
University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders.
How Different Treatments for Crohn's Effect the Microbiome
Different treatments for Crohn's disease in children affects their gut microbes in distinct ways, which has implications for future development of microbial-targeted therapies for these patients, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
Charting the 'Genomic Biography' of Leukemia
A new study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard offers a glimpse of the wealth of information that can be gleaned by combing the genome of a large collection of leukemia tissue samples.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos